Tests Ilumya with or without Halog ointment for psoriasis
Tests Ilumya injections, with or without Halog ointment, in adults with plaque psoriasis.
Plain-language title generated from the registry record
Registry title: ILUMYA in Combination With HALOG Ointment 0.1% for Plaque Psoriasis.
Key facts
- Where
- East Windsor, United StatesSee the site
- Phase
- Phase 4
Where in United States
- Psoriasis Treatment Center of Central New JerseyEast Windsor, United StatesTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Psoriasis Treatment Center of Central New Jersey
- Trial code
- NCT04347473
- Record updated
- 15 April 2020
- Original description
Patient with moderate-to-severe plaque psoriasis will receive Ilumya with or without Halog ointment.Read full original descriptionShow less
A Single Center Study to Evaluate the Effectiveness and Safety of ILUMYA in Combination With HALOG Ointment 0.1% for the Treatment of Moderate to Severe Plaque Psoriasis.
Patient with moderate-to-severe plaque psoriasis will receive Ilumya with or without Halog ointment.
Inclusion: Male or female adult ≥ 18 years of age; Diagnosis of moderate-to-severe chronic plaque-type psoriasis as defined by; BSA 10%; PGA ≥3; PASI ≥12; Must be a candidate for phototherapy and/or systemic therapy; Females of childbearing potential (FCBP) must have a negative serum pregnancy test at Screening and negative urine pregnancy test at Baseline. FCBP who engage in activity in which conception is possible must use one of the approved contraceptive options: hormonal contraception; intrauterine device (IUD); tubal ligation; or partner's vasectomy; Male or female condom diaphragm with spermicide, cervical cap with spermicide, or contraceptive sponge with spermicide.
Exclusion: Presence of significant uncontrolled medical condition that in the opinion of the investigator would affect patient safety during the trial; Active or untreated latent tuberculosis (TB); Non-plaque forms of psoriasis; Women of childbearing potential who are pregnant, intend to become pregnant, or are lactating.